Kanada - angličtina - Health Canada

hoffmann-la roche limited - mefloquine (mefloquine hydrochloride) - tablet - 250mg - mefloquine (mefloquine hydrochloride) 250mg - antimalarials

Kanada - angličtina - Health Canada

bayer inc - dienogest - tablet - 2mg - dienogest 2mg - progestins

Kanada - angličtina - Health Canada

bayer inc - estradiol valerate; estradiol valerate; dienogest; estradiol valerate; dienogest; estradiol valerate - tablet - 3mg; 2mg; 2mg; 2mg; 3mg; 1mg - estradiol valerate 3mg; estradiol valerate 2mg; dienogest 2mg; estradiol valerate 2mg; dienogest 3mg; estradiol valerate 1mg - contraceptives

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - acetate, quantity: 135 mmol/l; leucine, quantity: 5.9 g/l; valine, quantity: 5.5 g/l; arginine, quantity: 8.4 g/l; sulfate, quantity: 8 mmol/l; isoleucine, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; phenylalanine, quantity: 5.9 g/l; aspartic acid, quantity: 2.5 g/l; tyrosine, quantity: 0.17 g/l; tryptophan, quantity: 1.4 g/l; alanine, quantity: 12 g/l; chloride, quantity: 100 mmol/l; potassium, quantity: 50 mmol/l; glycine, quantity: 5.9 g/l; histidine, quantity: 5.1 g/l; threonine, quantity: 4.2 g/l; - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tryptophan, quantity: 1.9 g/l; arginine, quantity: 11.3 g/l; phenylalanine, quantity: 7.9 g/l; cysteine, quantity: 0.56 g/l; tyrosine, quantity: 0.23 g/l; glycine, quantity: 7.9 g/l; threonine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; alanine, quantity: 16 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); serine, quantity: 4.5 g/l; histidine, quantity: 6.8 g/l; proline, quantity: 6.8 - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; leucine, quantity: 5.9 g/l; tryptophan, quantity: 1.4 g/l; isoleucine, quantity: 4.2 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; histidine, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; valine, quantity: 5.5 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; methionine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; threonine, quantity: 4.2 g - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 12 g/l; glutamic acid, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; lysine hydrochloride, quantity: 8.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; tryptophan, quantity: 1.4 g/l; leucine, quantity: 5.9 g/l; potassium, quantity: 50 mmol/l; serine, quantity: 3.4 g/l; sulfate, quantity: 8 mmol/l; acetate, quantity: 135 mmol/l; methionine, quantity: 4.2 g/l; glycine, quantity: 5.9 g/l; cysteine hydrochloride, quantity: 0.61 g/l (equivalent: cysteine, qty 0.42 g - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); threonine, quantity: 4.2 g/l; proline, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; glutamic acid, quantity: 4.2 g/l; isoleucine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; methionine, quantity: 4.2 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; histidine, quantity: 5.1 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; tryptophan, quantity: 1.4 g/l; aspartic acid, quantity - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); glutamic acid, quantity: 5.6 g/l; threonine, quantity: 5.6 g/l; glycine, quantity: 7.9 g/l; aspartic acid, quantity: 3.4 g/l; tyrosine, quantity: 0.23 g/l; phenylalanine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; arginine, quantity: 11.3 g/l; alanine, quantity: 16 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; cysteine, quantity: 0.56 g/l; histidine, quantity: 6.8 g - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - general & plastic surgery - the echelon™ families of endoscopic linear cutters are intended for transaction, resection, and/or creation of anastomoses. the instruments have application in multiple open or minimally invasive general, gynecologic, urologic, thoracic, and pediatric surgical procedures. they can be used with staple line or tissue buttressing materials. the instruments may also be used for transaction and resection of liver parenchyma (hepatic vasculature and biliary structures), pancreas, kidney and spleen.